Pomalidomide-PEG3-azide is primarily utilized in the field of targeted drug delivery and bioconjugation. Its structure allows it to act as a linker, connecting therapeutic agents like pomalidomide to other molecules, such as antibodies or nanoparticles, enhancing their specificity and efficacy. This compound is particularly valuable in cancer research, where it aids in the development of antibody-drug conjugates (ADCs) or targeted therapies. The PEG3 spacer improves solubility and reduces immunogenicity, while the azide group enables click chemistry reactions for precise and efficient conjugation. This makes it a versatile tool in designing advanced treatments for diseases like multiple myeloma and other cancers.